<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00830674</url>
  </required_header>
  <id_info>
    <org_study_id>KRN23-US-02</org_study_id>
    <nct_id>NCT00830674</nct_id>
  </id_info>
  <brief_title>A Study of KRN23 in X-linked Hypophosphatemia</brief_title>
  <official_title>A Phase I, Double-blind, Randomized, Placebo-controlled, Single-dose, Dose-escalation Study of KRN23 in X-linked Hypophosphatemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Kirin Pharmaceutical Development, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the safety and tolerability of KRN23 after a
      single intravenous (IV) and subcutaneous (SC) administration in XLH patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Up to 7 weeks after dosing (maximally 11 weeks)</time_frame>
    <description>AEs, etc</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect to pharmacodynamic parameter</measure>
    <time_frame>Up to 7 weeks after dosing (maximally 11 weeks)</time_frame>
    <description>Change in Serum Phosphate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>X-linked Hypophosphatemia</condition>
  <arm_group>
    <arm_group_label>KRN23</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV or SC administration on day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single IV or SC administration on day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single dose IV or SC administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KRN23</intervention_name>
    <description>Single IV administration on day 1: 0.003, 0.01, 0.03, 0.1 and 0.3 mg/kg and Single SC administration on day 1: 0.1, 0.3, 0.6 and 1.0 mg/kg</description>
    <arm_group_label>KRN23</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years or older

          2. Clinical diagnosis of XLH

          3. TmP/GFR is less than 2.0 mg/dL

          4. GFR is 60 mL/min or above

        Exclusion Criteria:

          1. Have any sign of active infectious disease or have had an infection requiring
             treatment with antibiotics within three weeks prior to screening

          2. History of known immunodeficiency

          3. Lactating females, female patients who are pregnant or planning to become pregnant
             during the study

          4. Use of a pharmacologic vitamin D metabolite or its analog, phosphate, calcimimetics,
             and ingestion of aluminum hydroxide antacids within 10 days prior to screening and
             dosing

          5. Use of any supplement contained phosphate, calcium and/or vitamin D within 10 days
             prior to screening and dosing

          6. Receipt of live (attenuated) vaccine within 3-months prior to screening

          7. Have any condition which, in the opinion of the Investigator, could present a concern
             for either patient safety or difficulty with data interpretation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas O. Carpenter, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Clinical Research Center, Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Clinical Research Unit</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.gov/ct2/show/NCT01340482?term=KRN23&amp;rank=1</url>
    <description>KRN23-INT-002 An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia</description>
  </link>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2009</study_first_submitted>
  <study_first_submitted_qc>January 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2009</study_first_posted>
  <last_update_submitted>October 18, 2013</last_update_submitted>
  <last_update_submitted_qc>October 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>XLH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypophosphatemia</mesh_term>
    <mesh_term>Familial Hypophosphatemic Rickets</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

